Table 9

Efficacy, immunogenicity and safety of hepatitis A vaccination in patients with AIIRD

First author +ref.YearStudy designNo. casesEfficacyImmunogenicitySafetyInfluence of IS on eff./imm.LoE
Eff. Imm. Saf.
Rosdahl146 2018Cohort69 RA
58 HC
Reduced in RANo SAE
Mild systemic AE in 17% (HC and RA combined)
Askling145 2014Cohort53 RA:
15 anti-TNF
21 anti-TNF +MTX
17 MTX
Seroprotection in 10% after 1 month, 83% at month 7 (1 month after second dose)One meningoencephalitis 2.5 weeks after second dose
Mild AE in 2
Possibly reduced on MTX2b4
Van den Bijllaardt147 2013Cohort
173 IS-treated:
31 anti-TNF
19 Other
Reduced imm. on anti-TNF in multivariate regression analysis2b
  • AIIRD, autoimmune inflammatory rheumatic disease; DMARD, disease-modifying antirheumatic drug; eff., efficacy; HC, healthy control; imm., immunogenicity; IS, immunosuppressives; LoE, Level of evidence; MTX, methotrexate; No., number; RA, rheumatoid arthritis; ref., reference; (S)AE, (serious) adverse event; Saf., safety; TNF, tumor necrosis factor.